Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Down 47.7% in October

Avalon GloboCare Corp. (NASDAQ:ALBT) saw a significant decline in short interest in October. As of October 31st, there was short interest totalling 108,100 shares, a decline of 47.7% from the October 15th total of 206,700 shares. Based on an average daily volume of 905,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 27.4% of the shares of the stock are sold short.

Avalon GloboCare Trading Down 3.2 %

ALBT stock opened at $3.02 on Friday. The firm has a market cap of $3.23 million, a P/E ratio of -0.15 and a beta of 0.31. Avalon GloboCare has a 1-year low of $2.11 and a 1-year high of $21.60. The business’s 50 day moving average is $3.34 and its 200-day moving average is $4.89.

Avalon GloboCare (NASDAQ:ALBT) last released its quarterly earnings data on Monday, August 19th. The company reported ($2.85) earnings per share (EPS) for the quarter. The business had revenue of $0.33 million during the quarter.

About Avalon GloboCare

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.